Skip to main content

Table 3 Prevalence of mutational signatures

From: Mutational signatures among young-onset testicular cancers

Signature 20–29 30–39  > 40 p-value
(20–29 vs. > 40)
p-value
(30–39 vs. > 40)
p-value
(continuous age)
Signature 1 16 (40%) 16 (39%) 2 (10%) 0.12 0.047* 0.14
Signature 3 35 (88%) 34 (83%) 18 (90%) 0.69 0.41 0.54
Signature 6 17 (42%) 13 (32%) 10 (50%) 0.40 0.15 0.55
Signature 8 14 (35%) 14 (34%) 0 (0%) NA NA 0.020*
Signature 11 3 (8%) 2 (5%) 6 (30%) 0.10 0.026* 0.010*
Signature 13 5 (12%) 6 (15%) 3 (15%) 0.64 0.73 0.29
Signature 15 11 (28%) 11 (27%) 5 (25%) 0.43 0.78 0.51
Signature 16 16 (40%) 16 (39%) 14 (70%) 0.034* 0.032* 0.13
Signature 19 12 (30%) 17 (41%) 5 (25%) 0.85 0.23 0.80
Signature 20 6 (15%) 8 (20%) 3 (15%) 0.83 0.73 0.90
Signature 24 21 (52%) 17 (41%) 9 (45%) 0.69 0.80 0.55
Signature 26 2 (5%) 6 (15%) 4 (20%) 0.22 0.84 0.49
Signature 29 14 (35%) 12 (29%) 2 (10%) 0.039* 0.085 0.036*
Signature 30 28 (70%) 23 (56%) 10 (50%) 0.23 0.82 0.32
  1. Prevalence of COSMIC mutational signatures among testicular tumors diagnosed at ages 20–29 (n = 40), 30–39 (n = 41), and age 40 or older (n = 20). Entries are number (proportion) of cases with a signature present above a threshold of 6% in each age of onset group. Differences in signatures by age at onset groups were tested using a logistic regression model * indicates statistical significance at a .05 level